Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
P/S ratio for Silk Road Medical, Inc (SILK)
P/S ratio as of 2023: 2.69
According to Silk Road Medical, Inc's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.69. At the end of 2022 the company had a P/S ratio of 13.64.
P/S ratio history for Silk Road Medical, Inc from 2017 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 2.69 |
| 2022 | 13.64 |
| 2021 | 14.54 |
| 2020 | 27.60 |
| 2019 | 14.63 |
| 2018 | 30.06 |
| 2017 | 61.03 |